Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. (DCPH) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · DCPH · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
20
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Deciphera Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
DCPH insider buying and selling by quarter
DCPH insider selling · DCPH insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
DCPH executive sell shares · DCPH board member insider trading · DCPH insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 22, 2024 | Brightstar Associates LLC 10 percent owner | Other | 48,136 | $481 | Form 4 |
| Feb 15, 2024 | Sherman Matthew L EVP & Chief Medical Officer | Award | 17,275 | — | Form 4 |
| Feb 16, 2024 | Sherman Matthew L EVP & Chief Medical Officer | Sale | 2,615 | $41K | Form 4 |
| Feb 15, 2024 | Kelly Thomas Patrick CFO | Award | 17,275 | — | Form 4 |
| Feb 16, 2024 | Kelly Thomas Patrick CFO | Sale | 3,010 | $47K | Form 4 |
| Feb 15, 2024 | Pitman Jama SVP, Chief Development Officer | Award | 10,000 | — | Form 4 |
| Feb 16, 2024 | Pitman Jama SVP, Chief Development Officer | Sale | 2,267 | $35K | Form 4 |
| Feb 15, 2024 | Pitman Jama SVP, Chief Development Officer | Award | 9,725 | — | Form 4 |
| Feb 15, 2024 | Dhanak Dashyant EVP & Chief Scientific Officer | Award | 17,275 | — | Form 4 |
| Feb 15, 2024 | Martin Daniel C. Chief Commercial Officer | Award | 9,725 | — | Form 4 |
| Feb 16, 2024 | Martin Daniel C. Chief Commercial Officer | Sale | 2,267 | $35K | Form 4 |
| Feb 7, 2024 | Brightstar Associates LLC 10 percent owner | Other | 914,001 | $9K | Form 4 |
| Jan 16, 2024 | Sherman Matthew L EVP & Chief Medical Officer | Sale | 2,435 | $35K | Form 4 |
| Jan 16, 2024 | Pitman Jama SVP, Chief Development Officer | Sale | 1,624 | $23K | Form 4 |
| Jan 16, 2024 | Kelly Thomas Patrick CFO | Sale | 2,435 | $35K | Form 4 |
| Jan 16, 2024 | Martin Daniel C. Chief Commercial Officer | Sale | 1,624 | $23K | Form 4 |
| Dec 12, 2023 | Hoerter Steven L. President and CEO · Director | Award | 62,500 | — | Form 4 |
| Dec 13, 2023 | Hoerter Steven L. President and CEO · Director | Sale | 30,664 | $471K | Form 4 |
| Dec 12, 2023 | Kelly Thomas Patrick CFO | Award | 8,244 | — | Form 4 |
| Dec 13, 2023 | Kelly Thomas Patrick CFO | Sale | 2,792 | $43K | Form 4 |
| Dec 12, 2023 | Pitman Jama See Remarks | Award | 5,576 | — | Form 4 |
| Dec 13, 2023 | Pitman Jama See Remarks | Sale | 1,662 | $26K | Form 4 |
| Dec 12, 2023 | Martin Daniel C. Chief Commercial Officer | Award | 5,576 | — | Form 4 |
| Dec 13, 2023 | Martin Daniel C. Chief Commercial Officer | Sale | 1,727 | $27K | Form 4 |
| Dec 12, 2023 | Sherman Matthew L EVP & Chief Medical Officer | Award | 8,244 | — | Form 4 |
Brightstar Associates LLC
10 percent owner
Date
Apr 22
Shares
48,136
Price
$0.01
Value
$481
Sherman Matthew L
EVP & Chief Medical Officer
Date
Feb 15
Shares
17,275
Price
—
Value
—
Sherman Matthew L
EVP & Chief Medical Officer
Date
Feb 16
Shares
2,615
Price
$15.62
Value
$41K
Pitman Jama
SVP, Chief Development Officer
Date
Feb 15
Shares
10,000
Price
—
Value
—
Pitman Jama
SVP, Chief Development Officer
Date
Feb 16
Shares
2,267
Price
$15.62
Value
$35K
Pitman Jama
SVP, Chief Development Officer
Date
Feb 15
Shares
9,725
Price
—
Value
—
Dhanak Dashyant
EVP & Chief Scientific Officer
Date
Feb 15
Shares
17,275
Price
—
Value
—
Martin Daniel C.
Chief Commercial Officer
Date
Feb 15
Shares
9,725
Price
—
Value
—
Martin Daniel C.
Chief Commercial Officer
Date
Feb 16
Shares
2,267
Price
$15.62
Value
$35K
Brightstar Associates LLC
10 percent owner
Date
Feb 7
Shares
914,001
Price
$0.01
Value
$9K
Sherman Matthew L
EVP & Chief Medical Officer
Date
Jan 16
Shares
2,435
Price
$14.47
Value
$35K
Pitman Jama
SVP, Chief Development Officer
Date
Jan 16
Shares
1,624
Price
$14.47
Value
$23K
Martin Daniel C.
Chief Commercial Officer
Date
Jan 16
Shares
1,624
Price
$14.47
Value
$23K
Hoerter Steven L.
President and CEO · Director
Date
Dec 12
Shares
62,500
Price
—
Value
—
Hoerter Steven L.
President and CEO · Director
Date
Dec 13
Shares
30,664
Price
$15.37
Value
$471K
Martin Daniel C.
Chief Commercial Officer
Date
Dec 12
Shares
5,576
Price
—
Value
—
Martin Daniel C.
Chief Commercial Officer
Date
Dec 13
Shares
1,727
Price
$15.37
Value
$27K
Sherman Matthew L
EVP & Chief Medical Officer
Date
Dec 12
Shares
8,244
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About DCPH insider trading
DCPH insider trades
Deciphera Pharmaceuticals, Inc. (DCPH) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including DCPH. Over the past 12 months, 0 insiders have filed transactions with the SEC. DCPH insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Deciphera Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
DCPH insider trading · 5 questionsThe insiders of Deciphera Pharmaceuticals, Inc. (DCPH) include executives and directors such as DCPH, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026